Upcoming Data Management Transitions and Their Impact on Advanced Therapy Supply Chains

Thursday, October 28, 2021 16:00 - 17:00 PM BST

The future for global advanced therapy shipments requiring critical chain of custody, chain of condition and Chain of Compliance® near real-time reporting are facing a significant technology change.
In February 2022, 2G/3G networks are sunsetting in the United States and immediately transitioning to only leveraging 4G/LTE networks. Other countries and regions will continue to leverage 2G/3G networks and will decommission them at different rates.
The global shift towards 4G/LTE networks and moving away from 2G/3G is not without its complications. As networks continue to decommission 2G/3G networks globally, technology challenges relating to capacity and connectivity will impact all carrier services as well as packaging technology providers.
Join Cryoport Systems’ free webinar to learn about the upcoming network transitions, the associated challenges with the technology changes, and how you can ensure the certainty of global coverage and data fidelity for your cell and gene therapy shipments.
Topics in this presentation include:
  • North America’s Global Cellular Network Background and Current Status
  • Current State of the Supply Chain for High Technology Components Globally
  • Government, Aircraft, and Country Changes to Meet  Regulatory Requirements
  • Next Generation Solutions for Logistics and Monitoring to meet Cell and Gene Therapy Industry Needs

Quin Waddell, Director – Monitoring Solutions, Cryoport Systems


Quin Waddell

Quin Waddell, Director – Monitoring Solutions, Cryoport Systems





Missed our last webinar? 
Overcoming the challenges of ATMP manufacturing with novel automated systems for cell expansion

The growing demand for Advanced Therapy Medicinal Products (ATMP) and the challenges owing to their manufacturing requires these processes to be standardized and compliant with GMP guidelines. Additionally, the main hurdle limiting the diffusion of these therapies is represented by their non-scalable manufacturing processes, leading to unsustainable production costs.

To find out more catch it on demand by clicking the button below 
Cell and Gene Therapies continue to offer exciting avenues as curative therapies for unmet patient needs in the ultra-rare, rare, and beyond rare clinical indications. To serve these unmet needs, cell and gene therapy companies are developing multiple products that are expected to rapidly advance from pre-clinical stages to clinical trials. 
Although development of every product may present a unique set of challenges, leveraging a manufacturing platform can help overcome specific barriers to the clinic. FUJIFILM Diosynth Biotechnologies’ (FDB) AAV manufacturing platform offers clients access to an end-to-end service, including a fully characterized, suspension adapted, clonal HEK293 cGMP cell line, research and cGMP-grade Rep/Cap, Helper, and GOI (backbone) plasmids, accelerating process development, in addition to a comprehensive array of analytical methods to support phase-appropriate product characterization and batch release testing. FDB’s AAV platform and process development & manufacturing approaches to other viral vectors will be discussed in this presentation.

Get involved with Advanced Therapies Congress


To sponsor or exhibit

Jessica Robinson
Jessica.Robinson @terrapinn.com
+44 207 092 1150



To speak

Jessica Robinson
+44 (0)207 092 1150